Veniron 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 300.00

Medicine Details

Category Details
Generic Iron sucrose
Company Beximco pharmaceuticals ltd

Therapeutic Class

  • Parenteral Iron Preparations

Indications

  • Treatment of Veniron deficiency in patients with clinical need for rapid Veniron supply
  • Patients intolerant to oral Veniron therapy or non-compliant
  • Active inflammatory bowel disease where oral Veniron is ineffective
  • Non-dialysis dependent-chronic kidney disease patients receiving erythropoietin
  • Non-dialysis dependent-chronic kidney disease patients not receiving erythropoietin
  • Hemodialysis dependent-chronic kidney disease patients receiving erythropoietin
  • Peritoneal dialysis dependent-chronic kidney disease patients receiving erythropoietin
  • Treatment of Veniron deficiency anemia in surgical patients, blood donors, postpartum patients

Pharmacology

  • Iron Sucrose Injection USP is a brown, sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use
  • Contains approximately 30% Sucrose w/v (300 mg/ml) with pH of 10.5-11.1
  • Dissociates into Iron and Sucrose after administration
  • Iron is transferred from blood to liver and bone marrow
  • Ferritin binds and sequesters Iron in nontoxic form
  • Iron binds to plasma transferrin to supply tissues
  • Transferrin synthesis increased and ferritin production reduced in Iron deficiency
  • Elimination half-life: 6 hours, total clearance: 1.2 L/h
  • Iron mainly distributes in blood and to some extent in extravascular fluid, significant amount in liver, spleen, and bone marrow

Dosage

  • Adults and Elderly: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week depending on hemoglobin level
  • Children: Limited data, not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times per week depending on haemoglobin level

Administration

  • Intravenous injection: administered undiluted by slow intravenous injection at recommended rate
  • Maximum of 10 ml Iron Sucrose Injection (200 mg Iron) per injection
  • Test dose recommended before therapeutic dose in new patients
  • Infusion: preferably administered by drip infusion in dilution of 1 ml Iron Sucrose Injection (20 mg Iron) in max. 20 ml 0.9% w/v Sodium Chloride
  • Infusion time based on Iron amount

Interaction

  • Not studied, should not be administered concomitantly with oral iron preparations
  • Oral iron therapy not recommended until 5 days after last injection

Contraindications

  • Patients with evidence of Iron overload
  • Known hypersensitivity to Iron Sucrose or its inactive components
  • Anaemia not caused by Iron deficiency
  • History of allergic disorders, asthma, eczema, anaphylaxis, liver disease, infections

Side Effects

  • Hypotension, cramps/leg cramps, nausea, headache, vomiting, diarrhea
  • Body as a Whole: fever, pain, asthenia, malaise
  • Cardiovascular Disorders: chest pain, hypertension, hypervolemia
  • Gastrointestinal Disorders: abdominal pain, elevated liver enzymes
  • Central and Peripheral Nervous System: dizziness
  • Musculoskeletal System: musculoskeletal pain
  • Respiratory System: dyspnea, pneumonia, cough
  • Skin and appendages: pruritus, application site reaction
  • Hypersensitivity reactions: wheezing, dyspnea, rashes, pruritus, anaphylactic shock, loss of consciousness, bronchospasm, convulsion

Pregnancy & Lactation

  • Pregnancy Category-B, use only if clearly needed
  • Not known if excreted in human milk, caution during nursing

Precautions & Warnings

  • Caution for tissue Iron overload
  • Periodic monitoring of hematologic and haematinic parameters
  • Hypersensitivity Reactions: observed rarely, mild or moderate
  • Hypotension: reported in hemodialysis patients, related to rate and total dose administered

Use in Special Populations

  • Safety and effectiveness not established in pediatric patients
  • No overall differences in safety observed between elderly and younger subjects
  • Greater sensitivity of some older individuals cannot be ruled out

Overdose Effects

  • Excess may lead to accumulation and hemosiderosis
  • Symptoms: hypotension, headache, vomiting, nausea, dizziness, joint aches, paresthesia, abdominal and muscle pain, edema, cardiovascular collapse
  • Successfully treated with IV fluids, hydrocortisone, antihistamines

Storage Conditions

  • Store in cool (15°C-30°C) & dry place, protected from light
  • Keep out of the reach of children, do not freeze

Related Brands